Market Size
The global transcriptomics technologies market reached USD 7.36 billion in 2025 and is expected to reach USD 20.64 billion by 2033, growing at a CAGR of 14.6% during the forecast period from 2026 to 2033.
The market is witnessing strong growth driven by the rapid advancement of genomics research, increasing adoption of RNA sequencing technologies, and the expanding role of transcriptomics in understanding gene expression and disease mechanisms.
Market growth is strongly supported by rising demand for precision medicine, growing investments in life sciences research, and increasing use of transcriptomics in drug discovery and development. Technological advancements such as next-generation sequencing (NGS), single-cell transcriptomics, and spatial transcriptomics are significantly enhancing data accuracy and resolution. Additionally, expanding applications in oncology, infectious diseases, and rare genetic disorders are accelerating market adoption. Supportive regulatory frameworks, increasing funding from public and private sectors, and expanding biopharmaceutical pipelines are further contributing to market expansion.
Transcriptomics technologies play a critical role in enabling deeper insights into cellular function, disease progression, and therapeutic response. The integration of AI-driven analytics, bioinformatics platforms, and cloud-based data management is transforming how large-scale genomic data is processed and interpreted. Furthermore, continuous innovation in sequencing technologies, sample preparation methods, and automation is improving efficiency and scalability. With increasing focus on personalized healthcare, advanced research capabilities, and technological innovation, the transcriptomics technologies market is poised for sustained growth and significant impact across modern healthcare and life sciences.
Market Scope
| Metrics | Details |
| CAGR | 14.6% |
| Size Available for Years | 2023-2033 |
| Forecast Period | 2026-2033 |
| Data Availability | Value (US$) |
| Segments Covered | Injury Type, End User |
| Regions Covered | North America, Europe, Asia-Pacific, South America and Middle East & Africa |
| Fastest Growing Region | Asia-Pacific |
| Largest Region | North America |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, Porter’s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis and Other key Insights. |
For more details on this report – Request for Sample
Market Dynamics
Technological advancements and initiatives taken by manufacturers in next-generation sequencing are expected to drive the growth of the market.
The rapid cost drop and advancements in next-generation sequencing have made profiling cells at the individual level a conventional practice in scientific laboratories worldwide. Single-cell transcriptomics [single-cell RNA sequencing (SC-RNA-seq)] has an immense potential of uncovering the novel basis of human life. The well-known heterogeneity of cells at the individual level is better studied by single-cell transcriptomics.
The introduction of new microarrays is expected to propel growth of the global transcriptomics technologies market over the forecast period. For instance, in March 2020, Agilent Technologies Inc. launched Agilent GenetiSure Cyto microarrays for prenatal and postnatal research.
In addition, initiatives to advance personalized medicine are also expected to boost the growth of the market. For instance, in April 2020, Indivumed GmbH, an oncology company, launched the Oncology Alliance for Individualized Medicine, an international collaborative alliance to advance personalized medicine in cancer through IndivuType, the company’s multi-omics database
Drawbacks of RNA-seq genomic and transcriptomic data into mechanistic models of signaling pathways are expected to hamper the market's growth.
RNA-seq genomic performs many tasks but has two major drawbacks. First, the genomic information contained in the RNA-Seq reads usually remains unused. However, genomic variants, which may contain crucial information about the functionality and potential activity of the resulting proteins in the different processes where they participate, can be retrieved from such sequences. In this sense, it is well known that RNA-Seq has some limitations for DNA variant calling. There are two main points to consider lowly expressed genes include lower depth. Hence, variant calling is harder in those regions, and the detection of heterozygous variants can be limited due to allele-specific gene expression.
The second major drawback is that conventional functional analysis strategies are mainly descriptive and very limited in providing biological insights into the underlying molecular mechanisms that produce the observed phenotypic responses. Hence, the drawbacks of RNA-seq genomic and transcriptomic data into mechanistic models of signaling pathways are expected to hamper the market's growth.
Lack of efficient data analysis tools and complex data management are likely to hinder the market growth
With growing technological advancements, there has been an increasing concern related to the data complexity post-analysis of transcripts through sequencing platforms. Complex data management is one of the major limitations faced in transcriptome research. The data complexity is high and further increases with advances in the subsequent RNA analysis methodologies. Hence, the lack of efficient data analysis tools is expected to hinder the growth of the market.
Recent Developments
February 2026: Across North America, Europe, and Asia Pacific, rising demand for precision medicine and increasing applications in disease diagnosis significantly accelerated adoption of transcriptomics technologies, particularly in oncology and chronic disease research.
January 2026: Globally, advancements in RNA sequencing and next-generation sequencing platforms improved high-throughput gene expression analysis, enabling deeper insights into cellular functions and disease mechanisms.
December 2025: Leading companies such as Illumina, Thermo Fisher Scientific, Agilent Technologies, Bio-Rad Laboratories, and Qiagen expanded investments in sequencing platforms, reagents, and bioinformatics tools to strengthen transcriptomics capabilities.
November 2025: Increasing adoption of single-cell transcriptomics enabled high-resolution analysis of cellular heterogeneity, significantly advancing research in immunology, neurology, and cancer biology.
October 2025: Rising integration of AI analytics and machine learning in transcriptomics improved interpretation of complex gene expression data, accelerating biomarker discovery and drug development.
September 2025: Across key regions including the United States, China, India, Germany, and Japan, increasing research funding, expansion of biotech infrastructure, and growing pharmaceutical R&D activities significantly supported market growth.
The market is rapidly evolving toward data-driven biology, where AI-powered analysis, advanced sequencing technologies, and large-scale genomic datasets are transforming drug discovery, diagnostics, and personalized healthcare solutions.
Competitive Landscape
The global transcriptomics technologies market is vast with the presence of local as well as global companies. Some of the key players that are contributing to the growth of the market include F. Hoffmann-La Roche Ltd., Kreatech Inc., Cytognomix Inc., Biological Industries Ltd, Oxford Gene Technology Ltd., Abbott Laboratories, Molecular Devices LLC, Thermo Fisher Scientific Inc., Qiagen N. V., Agilent Technologies Inc. and SciGene Corp.
Transcriptomics Technologies Market Key Companies to Watch
Thermo Fisher Scientific Inc.:
Overview:
Thermo Fisher Scientific Inc. was founded in 2006 and headquartered in Waltham, Massachusetts, U.S. It provides analytical instruments, equipment; reagents & consumables; and software & services – for research manufacturing, analysis, discovery, and diagnostic applications. The company’s premier brands include – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services. The company operates through four business segments, Analytical Instruments, Life Sciences Solutions, Laboratory Products and Services, and Specialty Diagnostics. The company provides next-generation sequencing products under the Life Sciences Solution business segment.
Product Portfolio:
Thermo Fisher Scientific Inc. has continuously into manufacturing of next-generation sequencing products. The company offers Ion GeneStudio S5 System, Ion Torrent Genexus System.
Why Purchase the Report?
- Visualize the composition of the transcriptomics technologies market segmentation by technology, application and region highlighting the key commercial assets and players.
- Identify commercial opportunities in transcriptomics technologies market by analyzing trends and co-development deals.
- Excel data sheet with thousands of data points of transcriptomics technologies market - level 4/5 segmentation.
- PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
- Technology mapping in excel for the key technology of all major market players
The global transcriptomics technologies market report would provide an access to an approx.50market data table, 43 figures and 200 pages.
Target Audience
- End users/ Buyers
- Industry Investors/Investment Bankers
- Education & Research Institutes
- Research Professionals
- Emerging Companies
- Manufacturers
